| abstract |
The present invention relates to a dimeric protein fusion construct, wherein a portion of the protein is fused to either the CH1 domain or the CL domain of the antibody. These fusion constructs improve dimer protein stability, solubility, circulation half-life and production yield. For example, for blood clotting factors, the production of proteins already in active form containing two separate polypeptide chains avoids the activation steps required for single chain proteins, either artificially or in the patient's body Is particularly advantageous. |